Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4

被引:16
作者
Antonsson, L
Boketoft, A
Garzino-Demo, A
Olde, B
Owman, C
机构
[1] Lund Univ, Wallenberg Neurosci Ctr, Div Mol Neurobiol, SE-22184 Lund, Sweden
[2] Univ Maryland, Maryland Biotechnol Inst, Inst Human Virol, Baltimore, MD 21201 USA
关键词
HIV-1; chemokine; receptor; chimera; CCR5; CXCR4; ligand;
D O I
10.1097/00002030-200312050-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Mapping coreceptor epitopes used by the prototypic R5 and X4 strains, HIV-1(BaL) and HIV-1(IIIB), in comparison with epitopes involved in the activation and signaling induced by the natural ligands, RANTES and SDF-1beta. Design: Receptor hybrids between CCR5 and CXCR4 were constructed. Methods: Using single-overlap and extension PCR, increasing portions of CCR5 were replaced with corresponding parts of CXCR4. Viral interaction with these constructs was monitored in infection experiments using stably transfected cell lines, and ligand-induced activation of cells transiently expressing the constructs was measured in terms of calcium fluxes. Results: SDF-1beta required an essentially complete CXCR4, whereas RANTES demanded both the N terminus and the first two extracellular loops of CCR5. HIV-1 infection experiments emphasized the importance of the CCR5 N terminus for infection with HIV-1(BaL), whereas HIV-1(IIIB) was less demanding in its use of CXCR4. Conclusion: This study, for the first time monitoring CCR5 and CXCR4 ligand activation and HIV-1 interaction concomitantly, indicates that ligands and virus use different receptor epitopes which, in turn, vary between the two receptors. One particular chimera (FC-4b), having its junctional region close to the conserved cysteine in ECL2, functioned as coreceptor for both HIV-1(BaL) and HIV-1(IIIB), but was not activated with RANTES or SDF-1beta. The results provide a basis for tailoring drugs that block viral entry through the two major coreceptors without interfering with their physiological function. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:2571 / 2579
页数:9
相关论文
共 50 条
  • [41] HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro
    Moncunill, Gemma
    Armand-Ugon, Mercedes
    Pauls, Eduardo
    Clotet, Bonaventura
    Este, Jose A.
    AIDS, 2008, 22 (01) : 23 - 31
  • [42] Does cyclosporin a affect CCR5 and CXCR4 expression in primary HIV-1-Infected patients?
    Biswas, Priscilla
    Galli, Andrea
    Galli, Laura
    Din, Chiara Tassan
    Vecchi, Andrea
    Malnati, Mauro
    Lazzarin, Adriano
    Tambussi, Giuseppe
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2007, 72B (06) : 433 - 441
  • [43] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
    Seibert, Christoph
    Ying, Weiwen
    Gavrilov, Svetlana
    Tsamis, Fotini
    Kuhmann, Shawn E.
    Palani, Anandan
    Tagat, Jayaram R.
    Clader, John W.
    McCombie, Stuart W.
    Baroudy, Bahige M.
    Smith, Steven O.
    Dragic, Tatjana
    Moore, John P.
    Sakmar, Thomas P.
    VIROLOGY, 2006, 349 (01) : 41 - 54
  • [44] Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4
    N Zhou
    J Fang
    M Mukhtar
    E Acheampong
    RJ Pomerantz
    Gene Therapy, 2004, 11 : 1703 - 1712
  • [45] Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
    Choi, Won-Tak
    Yang, Yilei
    Xu, Yan
    An, Jing
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (13) : 1574 - 1589
  • [46] Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4
    Zhou, N
    Fang, J
    Mukhtar, M
    Acheampong, E
    Pomerantz, RJ
    GENE THERAPY, 2004, 11 (23) : 1703 - 1712
  • [47] Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors
    Toma, Jonathan
    Whitcomb, Jeannette M.
    Petropoulos, Christos J.
    Huang, Wei
    AIDS, 2010, 24 (14) : 2181 - 2186
  • [48] Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV
    Freen-van Heeren, Julian J. J.
    BIOTECH, 2022, 11 (03):
  • [49] The first structure of HIV-1 gp120 with CD4 and CCR5 receptors
    Guan, Yongjun
    CELL AND BIOSCIENCE, 2019, 9 (1)
  • [50] Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)
    Ruff, MR
    Melendez-Guerrero, LM
    Yang, QE
    Ho, WZ
    Mikovits, JW
    Pert, CB
    Ruscetti, FA
    ANTIVIRAL RESEARCH, 2001, 52 (01) : 63 - 75